<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02543294</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0379</org_study_id>
    <nct_id>NCT02543294</nct_id>
  </id_info>
  <brief_title>REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)</brief_title>
  <official_title>REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to learn if heart function remains normal after stopping
      heart failure medication in patients who have received chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If you agree to take part in this study, the following baseline tests and procedures will be
      performed on Day 1:

        -  Your complete medical history will be recorded.

        -  You will have a physical exam, including measurement of your vital signs (blood
           pressure, heart rate, and breathing rate).

        -  You will complete a questionnaire about any symptoms you may be having. The
           questionnaire should take about 5-10 minutes to complete.

        -  You will have an echocardiogram (ECHO) and an electrocardiogram (ECG) to check your
           heart function.

        -  You will have blood (about 3 tablespoons) drawn for routine tests. If you can become
           pregnant, part of this blood draw will be used for a pregnancy test. To take part in
           this study, you must not be pregnant.

        -  You will be given instructions on how to gradually wean yourself off of your heart
           failure medication.

        -  You will be given a machine that you will use to measure your blood pressure at home.

      You will be asked to monitor your blood pressure and heart rate at home daily and keep the
      results in a diary. You should bring your diary to each study visit.

      At Month 1:

        -  You will have a physical exam, including measurement of your vital signs.

        -  You will complete the questionnaire about any symptoms you may be having.

        -  You will have blood (about 2 teaspoons) drawn for routine tests.

      At Months 2, 4, 6, 12, 18, and 30:

        -  You will have a physical exam, including measurement of your vital signs.

        -  You will complete the questionnaire about any symptoms you may be having.

        -  You will have an ECHO.

        -  You will have blood (about 2 teaspoons) drawn for routine tests.

      At Months 3 and 5, you will have a telephone follow-up with a member of the research team.

      Length of Study Participation:

      You may continue taking part in the study for up to 6 continuous months with follow-up visits
      at Months 12, 18, and 30. You will no longer be able to take part if the disease gets worse,
      if intolerable side effects occur, or if you are unable to follow study directions.

      This is an investigational study.

      Up to 45 participants will be enrolled in this study. All will take part at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2012</start_date>
  <completion_date type="Actual">September 10, 2017</completion_date>
  <primary_completion_date type="Actual">September 10, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Percentage of Cancer Survivors That Maintain Left Ventricular Ejection Fraction (LVEF) ≥50% After Discontinuing Cardiac Medications: Beta Blockers, Angiotensin Converting Enzyme Inhibitors (ACE-I), or Angiotensin Receptor Blockers (ARB).</measure>
    <time_frame>A total of 30 months from enrollment date of each participant;</time_frame>
    <description>A withdrawal failure is defined as a decrease in the LVEF when cardiac medications are discontinued as determined by echocardiogram to LVEF&lt;50% or a decrease by 10% from baseline measurement. Maintenance of LVEF is defined as LVEF≥50%. LVEF was assessed at Baseline, Months 2, 4, 6, 12, 18, &amp; 30.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk Factors to Predict Early Decline of Myocardial Function During the Weaning of HF (Heart Failure) Medications.</measure>
    <time_frame>A total of 30 months from enrollment date of each participant</time_frame>
    <description>To identify an increased troponin-I that can predict the possibility of HF medication withdrawal failure.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cancer Treatment Induced Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>Anthracycline Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herceptin Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of Treatments Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Echocardiograms</intervention_name>
    <description>Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.</description>
    <arm_group_label>Anthracycline Treatment Group</arm_group_label>
    <arm_group_label>Combination of Treatments Group</arm_group_label>
    <arm_group_label>Herceptin Treatment Group</arm_group_label>
    <other_name>ECHO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrocardiogram</intervention_name>
    <description>Electrocardiogram performed at baseline.</description>
    <arm_group_label>Anthracycline Treatment Group</arm_group_label>
    <arm_group_label>Combination of Treatments Group</arm_group_label>
    <arm_group_label>Herceptin Treatment Group</arm_group_label>
    <other_name>ECG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Symptom Questionnaire</intervention_name>
    <description>Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.</description>
    <arm_group_label>Anthracycline Treatment Group</arm_group_label>
    <arm_group_label>Combination of Treatments Group</arm_group_label>
    <arm_group_label>Herceptin Treatment Group</arm_group_label>
    <other_name>Survey</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone Follow-Up</intervention_name>
    <description>Telephone follow-up by study staff at months 3 and 5.</description>
    <arm_group_label>Anthracycline Treatment Group</arm_group_label>
    <arm_group_label>Combination of Treatments Group</arm_group_label>
    <arm_group_label>Herceptin Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cancer survivors with no evidence of disease for at least 6 months as determined by
             the oncologist and no longer receiving cancer treatment.

          2. Prior diagnosis of CILVD with recovered LVEF (i.e. improved to &gt; 50%) for at least 6
             months with recommended HF medications (ACE-I or ARB and/or B-blocker).

          3. Absence of other causes of cardiomyopathy (e.g. ischemia, hypertension, amyloidosis,
             or hemochromatosis) per chart review of the clinician's documentation

          4. Documented normal LVEF for at least 6 months after the initiation of recommended HF
             therapy.

          5. Age 18 - 80 years. HF clinical guidelines is supported by evidenced-based data from
             clinical trials which includes individuals up to 80 years of age.

          6. Residence within the United States.

          7. Ability to read and write English, because the MD Anderson Symptom Inventory -Heart
             Failure (MDASI-HF) instrument (Fadol et al., 2008) has been validated in English only.

        Exclusion Criteria:

          1. Participants will be excluded if they have a recurrence that requires anti-cancer
             treatment.

          2. Have a documented history of hypertension, coronary artery disease, myocardial
             infarction, diabetes mellitus, amyloidosis or hemochromatosis.

          3. Exhibiting HF symptoms (e.g. shortness of breath, edema).

          4. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anecita Fadol, PHD, MSN</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 4, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <results_first_submitted>May 1, 2018</results_first_submitted>
  <results_first_submitted_qc>January 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Echocardiogram</keyword>
  <keyword>ECHO</keyword>
  <keyword>Electrocardiogram</keyword>
  <keyword>ECG</keyword>
  <keyword>Questionnaire</keyword>
  <keyword>Survey</keyword>
  <keyword>Telephone Follow-Up</keyword>
  <keyword>HF</keyword>
  <keyword>Cancer treatment induced left ventricular dysfunction</keyword>
  <keyword>CILVD</keyword>
  <keyword>Left ventricular ejection fraction</keyword>
  <keyword>LVEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02543294/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were identified in the Cardiology outpatient clinic at MD Anderson Cancer Center by research team. Team reviewed cardiac medications (angiotensin-converting-enzyme inhibitor (ACE-I), angiotensin II receptor blocker (ARB), and beta blocker), met with eligible patients, explained study, obtained informed consent, and enrolled in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention (Weaning)</title>
          <description>Down titrated current dose by half each week until medication is off. Weaning order: ACE-I, ARB, and beta blocker.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients at MD Anderson that met inclusion criteria (specified in Recruitment Details) and not excluded due to: Cancer recurrence; documented history of hypertension, coronary artery disease, myocardial infarction, diabetes mellitus, amyloidosis or hemochromatosis; presence of HF symptoms (e.g. shortness of breath, edema); Pregnancy.</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention (Weaning)</title>
          <description>Down titrated current dose by half each week until medication is off. Weaning order: ACE-I, ARB, and beta blocker.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Maintenance of LVEF ≥50% after weaning of heart failure medications.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.9" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 30-39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 40-49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 50-59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left ventricular ejection fraction (LVEF) ≥50%</title>
          <description>LVEF ≥50%, taking heart failure medications classified as Angiotension converting enzyme inhibitors (ACE-Inhibitors), Beta-blockers, and/or angiotension-receptor blockers (ARBs), no diabetes, no hypertension, no arrhythmias, cancer in remission for at least 6 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine the Percentage of Cancer Survivors That Maintain Left Ventricular Ejection Fraction (LVEF) ≥50% After Discontinuing Cardiac Medications: Beta Blockers, Angiotensin Converting Enzyme Inhibitors (ACE-I), or Angiotensin Receptor Blockers (ARB).</title>
        <description>A withdrawal failure is defined as a decrease in the LVEF when cardiac medications are discontinued as determined by echocardiogram to LVEF&lt;50% or a decrease by 10% from baseline measurement. Maintenance of LVEF is defined as LVEF≥50%. LVEF was assessed at Baseline, Months 2, 4, 6, 12, 18, &amp; 30.</description>
        <time_frame>A total of 30 months from enrollment date of each participant;</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention (Weaning)</title>
            <description>&quot;Weaning of Cardiac Medications Based on Therapeutic Category (i.e. Beta Blockers, ACE-I, ARB, or any combination of these medications.)&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Percentage of Cancer Survivors That Maintain Left Ventricular Ejection Fraction (LVEF) ≥50% After Discontinuing Cardiac Medications: Beta Blockers, Angiotensin Converting Enzyme Inhibitors (ACE-I), or Angiotensin Receptor Blockers (ARB).</title>
          <description>A withdrawal failure is defined as a decrease in the LVEF when cardiac medications are discontinued as determined by echocardiogram to LVEF&lt;50% or a decrease by 10% from baseline measurement. Maintenance of LVEF is defined as LVEF≥50%. LVEF was assessed at Baseline, Months 2, 4, 6, 12, 18, &amp; 30.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maintained (LVEF &lt;/= 50%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal Failure (LVEF &lt;50% or decrease of 10%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal by Subject</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Factors to Predict Early Decline of Myocardial Function During the Weaning of HF (Heart Failure) Medications.</title>
        <description>To identify an increased troponin-I that can predict the possibility of HF medication withdrawal failure.</description>
        <time_frame>A total of 30 months from enrollment date of each participant</time_frame>
        <population>The standard deviation is 0 because every value collected over the course of the entire study was 0.03. Mean would be 0.03 with a standard deviation of 0</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention (Weaning)</title>
            <description>Down titrated current dose by half each week until medication is off. Weaning order: ACE-I, ARB, and beta blocker.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors to Predict Early Decline of Myocardial Function During the Weaning of HF (Heart Failure) Medications.</title>
          <description>To identify an increased troponin-I that can predict the possibility of HF medication withdrawal failure.</description>
          <population>The standard deviation is 0 because every value collected over the course of the entire study was 0.03. Mean would be 0.03 with a standard deviation of 0</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Thirty (30) months from date of enrollment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention (Weaning)</title>
          <description>Weaning of Cardiac Medications Based on Therapeutic Category (i.e. Beta Blockers, ACE-I, ARB, or any combination of these medications.)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease in Ejection fraction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anecita P. Fadol,PHD/Associate Professor, Department of Nursing</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-8397</phone>
      <email>afadol@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

